Ekso Bionics (EKSO) Posts Earnings Results, Misses Expectations By $0.03 EPS

Ekso Bionics (NASDAQ:EKSO) issued its quarterly earnings data on Monday. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03), Fidelity Earnings reports. Ekso Bionics had a negative return on equity of 246.15% and a negative net margin of 396.04%. The firm had revenue of $2.52 million for the quarter, compared to analyst estimates of $2.98 million.

EKSO stock traded down $0.05 during trading on Tuesday, hitting $1.69. 189,811 shares of the company’s stock were exchanged, compared to its average volume of 508,540. The stock has a market cap of $106.22 million, a price-to-earnings ratio of -1.90 and a beta of -0.63. Ekso Bionics has a 52-week low of $0.99 and a 52-week high of $4.77. The company has a quick ratio of 3.48, a current ratio of 3.81 and a debt-to-equity ratio of 0.23.

A number of research analysts have weighed in on the company. ValuEngine upgraded Ekso Bionics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Zacks Investment Research upgraded Ekso Bionics from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Earnings History for Ekso Bionics (NASDAQ:EKSO)

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply